In my view, the 23% & 33% ⬇️ in first & total hospitalised HF w/ SGLT2i post-MI is a welcome finding, consistent w/the totality of the evidence Difficulty for any trial to demonstrate ⬇️ in all-cause mortality over median F/U 18 months given the standard-of-care in 2024 #ACC24 Tweet added by Brendon Neuen @brendonneuen

Brendon Neuen

3 months

In my view, the 23% & 33% ⬇️ in first & total hospitalised HF w/ SGLT2i post-MI is a welcome finding, consistent w/the totality of the evidence Difficulty for any trial to demonstrate ⬇️ in all-cause mortality over median F/U 18 months given the standard-of-care in 2024 #ACC24

NEJM

@NEJM

3 months

EMPACT-MI trial: Among patients hospitalized for acute myocardial infarction and at risk for heart failure, empagliflozin did not lead to a significantly lower risk of a first heart-failure hospitalization or death from any cause than placebo. #ACC24

2

169

359

2

14

53

Eric Weinhandl

@eric_weinhandl

3 months

@brendonneuen It's pretty clear that HR = 1 for the first 6 mo and that HR <1 (by a wide margin) afterward. One would need to take a very narrow view of the 'main effect' to view this trial as negative.

0

1

Das

@shivadas29

3 months

@brendonneuen There is a similar trial known as DAPA-MI ongoing

0

Replies